Physician profile
Chinya Murali
NPI 1831156868
$8,543.61
in general payments reported to CMS, 2019-2025
32 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 88% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $572 · 2021: $533 · 2022: $1,273 · 2023: $1,599 · 2024: $1,613 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.97 |
| Education | $216.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,310.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $779.32 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $694.92 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $665.17 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $645.73 | 2020-2025 | Caplyta |
| Alkermes, INC. | $535.84 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $533.45 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $483.03 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $470.11 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $426.21 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $417.41 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $327.46 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $211.12 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $181.03 | 2022-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $141.18 | 2020-2023 | Belsomra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $96.58 | 2020-2022 | |
| Indivior INC. | $85.49 | 2021-2024 | Perseris |
| Noven Therapeutics, LLC | $84.24 | 2023-2024 | Xelstrym, Secuado |
| Allergan, INC. | $80.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $72.31 | 2021-2022 | |
| Neos Therapeutics, LP | $55.83 | 2019-2020 | |
| Almatica Pharma LLC | $41.43 | 2023 | Loreev Xr, Sertraline Hcl |
| Avanir Pharmaceuticals, INC. | $33.15 | 2019-2020 | |
| Sage Therapeutics, LLC | $30.91 | 2024 | |
| Acadia Pharmaceuticals INC | $24.34 | 2021 | |
| Validus Pharmaceuticals LLC | $24.17 | 2025 | Raldesy |
| Lilly USA, LLC | $18.03 | 2025 | Kisunla |
| Adlon Therapeutics L.P. | $17.64 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.29 | 2024 | |
| Bausch Health US, LLC | $16.22 | 2022 | |
| Shire North American Group INC | $11.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chinya Murali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.